Powered by

Adlon Therapeutics L.P. and Purdue Pharma L.P. to Present Six Scientific Posters at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting; Data to include outcomes from a Phase 3 Adult Laboratory Classroom study to e

Jan 16, 2020 - Business Wire

Adlon Therapeutics L.P. and Purdue Pharma L.P. today announced that six posters highlighting PRC-063 data as well as research on real-world treatment patterns and patient preferences will be presented at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C. PRC-063 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older and is currentl...